Regeneron Pharmaceuticals Inc. buy jde
Summary
This prediction ended on 16.06.16 with a price of €325.62. Massive losses of -36.59% were the result for the BUY prediction by jde. jde has 50% into this predictionRegeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.
Performance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Regeneron Pharmaceuticals Inc. | 1.922% | 1.922% | 47.733% | 105.736% |
iShares Core DAX® | 0.786% | 1.251% | 11.561% | 16.636% |
iShares Nasdaq 100 | 1.855% | -2.687% | 25.316% | 43.346% |
iShares Nikkei 225® | 3.947% | 2.199% | 11.527% | 12.586% |
iShares S&P 500 | 1.787% | 0.151% | 23.699% | 42.958% |
Comments by jde for this prediction
In the thread Regeneron Pharmaceuticals Inc. diskutieren
Gute Bilanz, schönes Potential